LS-104

• UNSPSC Description:

  LS-104 (Tyrene CR-4) is a non-ATP-competitive kinase inhibitor against JAK2, Bcr-Abl and FLT3. LS-104 potently induces apoptosis in JAK2V617F-positive cells and inhibits JAK2 autophosphorylation and downstream signal transduction. LS-104 also inhibits proliferation and induces potent cytotoxic effects in FLT3 expressing leukemic cells. LS-104 is a hydroxystyryl-acrylonitrile compound, which is promising for research of myeloproliferative disorders and refractory/relapsed hematologic malignancies[1][2].

• Target Antigen:

  Apoptosis; Bcr-Abl; FLT3; JAK

• Type:

  Reference compound

• Related Pathways:

  Apoptosis;Epigenetics;JAK/STAT Signaling;Protein Tyrosine Kinase/RTK;Stem Cell/Wnt

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Cancer; Inflammation/Immunology; Cardiovascular Disease

• Assay Protocol:

  https://www.medchemexpress.com/ls-104.html

• Smiles:

  OC1=C(O)C=CC(/C=C/C=C(C#N)/C(NCC2=CC=CC=C2)=O)=C1

• Molecular Weight:

  320.34

• References & Citations:

  [1]Lipka DB, et al. LS104, a non-ATP-competitive small-molecule inhibitor of JAK2, is potently inducing apoptosis in JAK2V617F-positive cells. Mol Cancer Ther. 2008 May;7(5):1176-84.|[2]Kasper S, et al. The kinase inhibitor LS104 induces apoptosis, enhances cytotoxic effects of chemotherapeutic drugs and is targeting the receptor tyrosine kinase FLT3 in acute myeloid leukemia. Leuk Res. 2008 Nov;32(11):1698-708.

• Shipping Conditions:

  Room temperature

• Clinical Information:

  Phase 1

• CAS Number:

  368836-72-0